1224640-12-3

Basic information

• Product Name: 1-cyclopropyl-1,2,3,4-tetrahydroquinoxaline-2,3-dione
• CAS NO: 1224640-12-3
• Molecular Weight: 202.213
• Mol File: 1224640-12-3.mol

Chemical Properties

• CAS DataBase Reference: 1-cyclopropyl-1,2,3,4-tetrahydroquinoxaline-2,3-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 1-cyclopropyl-1,2,3,4-tetrahydroquinoxaline-2,3-dione(1224640-12-3)
• EPA Substance Registry System: 1-cyclopropyl-1,2,3,4-tetrahydroquinoxaline-2,3-dione(1224640-12-3)

Safety Data

• Hazardous Substances Data: 1224640-12-3(Hazardous Substances Data)

Usage

Heterocyclic compound

A compound containing a ring structure with at least one non-carbon atom In this case, the compound has a quinoxaline core structure with nitrogen atoms in the ring.

Cyclopropyl ring

A three-carbon ring with a specific structural arrangement The compound contains a cyclopropyl group, which is a small ring consisting of three carbon atoms.

Quinoxaline core structure

A heterocyclic aromatic compound consisting of two fused six-membered rings with nitrogen atoms at the 1, 2, 5, and 8 positions The compound's core structure is based on the quinoxaline system, which is known for its chemical stability and various biological activities.

Potential biological activities

Antitumor and antifungal properties 1-cyclopropyl-1,2,3,4-tetrahydroquinoxaline-2,3-dione has been studied for its possible effects on inhibiting the growth of cancer cells and fungi.

Therapeutic agent for neurodegenerative diseases

Being investigated for its potential use in treating conditions such as Alzheimer's and Parkinson's Researchers are exploring the possibility of using 1-cyclopropyl-1,2,3,4-tetrahydroquinoxaline-2,3-dione to slow down or prevent the progression of neurodegenerative diseases by targeting specific biological pathways.

Pharmaceutical industry interest

The chemical structure and properties make it an interesting target for further research and development Due to its unique structure and potential biological activities, the compound is a promising candidate for the development of new drugs and therapies.

Upstream product

• 88-74-4 2-nitro-aniline 
• 17293-40-2 ethyl 2-((2-nitrophenyl)amino)-2-oxoacetate 
• 411235-57-9 cyclopropylboronic acid 
• 1224640-10-1 N-cyclopropyl-N-(2-nitro-phenyl)-oxalamic acid methyl ester 
• 55432-23-0 cyclopropyl-(2-nitro-phenyl)-amine 
• 1493-27-2 ortho-nitrofluorobenzene 
• 1224640-11-2 1-cyclopropyl-4-hydroxy-1,2,3,4-tetrahydroquinoxaline-2,3-dione 

Downstream Products

• 1224640-13-4 1-cyclopropyl-1,2,3,4-tetrahydro-quinoxaline 
• 1315468-79-1 [4-(2,5-dichloro-4-bromophenoxy)pyridin-3-yl]-(4-cyclopropyl-3,4-dihydro-2H-quinoxalin-1-yl)methanone 
• 1315468-81-5 2,5-dichloro-4-[3-(4-cyclopropyl-3,4-dihydro-2H-quinoxaline-1-carbonyl)-pyridin-4-yloxy]-benzoic acid methyl ester 
• 1315468-83-7 4-chloro-5-[3-(4-cyclopropyl-3,4-dihydro-2H-quinoxaline-1-carbonyl)-pyridin-4-yloxy]-phthalic acid dimethyl ester 
• 1315468-84-8 {2,5-dichloro-4-[3-(4-cyclopropyl-3,4-dihydro-2H-quinoxaline-1-carbonyl)-pyridin-4-yloxy]-benzoylamino}-acetic acid methyl ester 
• 1315468-85-9 {2,5-dichloro-4-[3-(4-cyclopropyl-3,4-dihydro-2H-quinoxaline-1-carbonyl)-pyridin-4-yloxy]-benzoylamino}-acetic acid 
• 1315468-88-2 3-{2,5-dichloro-4-[3-(4-cyclopropyl-3,4-dihydro-2H-quinoxaline-1-carbonyl)-pyridin-4-yloxy]-benzoylamino}-propionic acid ethyl ester 
• 1315468-89-3 3-{2,5-dichloro-4-[3-(4-cyclopropyl-3,4-dihydro-2H-quinoxaline-1-carbonyl)-pyridin-4-yloxy]-benzoylamino}-propionic acid 
• 1315468-90-6 2-{2,5-dichloro-4-[3-(4-cyclopropyl-3,4-dihydro-2H-quinoxaline-1-carbonyl)-pyridin-4-yloxy]-benzoylamino}-ethanesulfonic acid 
• 1315468-93-9 2,5-dichloro-4-[3-(4-cyclopropyl-3,4-dihydro-2H-quinoxaline-1-carbonyl)-pyridin-4-yloxy]-N-(1 H-tetrazol-5-yl)-benzamide 
• 1315469-13-6 2,5-dichloro-4-[3-(4-cyclopropyl-3,4-dihydro-2H-quinoxaline-1-carbonyl)-pyridin-4-yloxy]-benzamide 
• 1315469-16-9 (4-cyclopropyl-3,4-dihydro-2H-quinoxalin-1-yl)-[4-(2,5-dichloro-4-hydroxymethyl-phenoxy)-pyridin-3-yl]-methanone 
• 1315469-17-0 2,5-dichloro-4-[3-(4-cyclopropyl-3,4-dihydro-2H-quinoxaline-1-carbonyl)-pyridin-4-yloxy]-benzonitrile 
• 1315469-18-1 (4-cyclopropyl-3,4-dihydro-2H-quinoxalin-1-yl)-[4-(2,5-dichloro-4-hydroxy-phenoxy)-pyridin-3-yl]-methanone 

Relevant articles and documents

Design, synthesis and evaluation of 3-phenoxypyrazine-2-carboxamide derivatives as potent TGR5 agonists

TGR5 is emerging as an important and promising target for the treatment of non-alcoholic steatohepatitis, type 2 diabetes mellitus (T2DM), and obesity. A series of novel 3-phenoxypyrazine-2-carboxamide derivatives were designed, synthesized and evaluated

Design, synthesis and evaluation of 1-benzyl-1H-imidazole-5-carboxamide derivatives as potent TGR5 agonists

TGR5 is emerging as an important and promising target for the treatment of diabetes, obesity and other metabolic syndromes. A series of novel 1-benzyl-1H-imidazole-5-carboxamide derivatives was designed, synthesized and evaluated in vitro and in vivo. The

PIII/PV=O Catalyzed Cascade Synthesis of N-Functionalized Azaheterocycles

An organocatalytic method for the modular synthesis of diverse N-aryl and N-alkyl azaheterocycles (indoles, oxindoles, benzimidazoles, and quinoxalinediones) is reported. The method employs a small-ring organophosphorus-based catalyst (1,2,2,3,4,4-hexamethylphosphetane P-oxide) and a hydrosilane reductant to drive the conversion of ortho-functionalized nitroarenes into azaheterocycles through sequential intermolecular reductive C?N cross coupling with boronic acids, followed by intramolecular cyclization. This method enables the rapid construction of azaheterocycles from readily available building blocks, including a regiospecific approach to N-substituted benzimidazoles and quinoxalinediones.

2-Phenoxy-nicotinamides are Potent Agonists at the Bile Acid Receptor GPBAR1 (TGR5)

Potency with potential: 2-Phenoxy- nicotinamides were identified as potent agonists at the GPBAR1 receptor, a target in the treatment of obesity, type2 diabetes and metabolic syndrome. Extensive structure-activity relationship studies supported by homolog

NON-SYSTEMIC TGR5 AGONISTS

Compounds of structure (I), or a stereoisomer, tautomer, pharmaceutically acceptable salt or prodrug thereof, wherein R1, R2, R3, R4, R8, R9, R10, R11, R12, A1, A2, X, Y and Z are as defined herein. Uses of such compounds as TGR5 antagonists and for treatment of various indications, including Type II diabetes meletus are also provided.

4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS

This invention relates to novel phenyl amide or pyridyl amide derivatives of the formula wherein A1, A2, B1, B2 and R1 to R11 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.

4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS

This invention relates to novel phenyl amide or pyridyl amide derivatives of the formula (I), wherein A1, A2, B1, B2 and R1 to R11 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.

NOVEL PHENYL AMIDE OR PYRIDYL AMIDE DERIVATIVES

This invention relates to novel phenyl amide or pyridyl amide derivatives of the formula wherein A1, A2, B1, B2 and R1 to R11 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.